Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEART-BEAT: Heart Rate Control Before Cardiac CT
NCT07268170Phase 3Enrolling by invitation
- Sponsor
- Regionshospitalet Gødstrup
- Start
- Dec 2025
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of metoprolol, atenolol and ivabradine in coronary artery disease (CAD) and ischemic heart disease (IHD) (9 arms), sponsored by Regionshospitalet Gødstrup. Primary endpoint: Dose and type of drugs with the swiftest heart rate reduction at 2 hours. Started Dec 2025; status: enrolling by invitation.
02
Drugs
metoprololatenololivabradine
03
Conditions
coronary artery disease (CAD)ischemic heart disease (IHD)
Beyond the preview
Go deeper on NCT07268170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07268170.